Squamous cell carcinomas represent the most common malignancies of the head and neck region. About two-thirds of patients with head and neck squamous cell carcinoma (HNSCC) exhibit advanced stage disease, usually involving regional lymph nodes ([@bib3]). Advanced HNSCC have often a poor prognosis despite intensive local treatment due to tumour recurrences and distant metastases. About 50--60% of patients with advanced disease develop local or regional recurrences after treatment ([@bib13]).

Known risk factors for the development of HNSCC are tobacco use and alcohol consumption ([@bib5]; [@bib31]), as well as human papillomavirus (HPV) infection, mainly type 16, which particularly increases the risk for tonsillar and oropharyngeal cancers ([@bib7]). Human papillomavirus-positive HNSCC tumours have a favourable prognosis ([@bib18]; [@bib4]) and show a better therapy response ([@bib3]). Thus, HPV status represents a valuable predictive biomarker that should be taken into consideration for treatment planning to prevent excessive therapy.

To date no biomarker for therapy monitoring or patient surveillance is established. Predictive biomarkers in the peripheral blood, such as the newly identified marker HSP70 in HNSCC patients ([@bib9]), provide a minimally invasive way to predict therapy outcome. Recently, it was shown that microRNAs (miRNAs) in plasma samples exhibit high stability and are resistant to RNase activity ([@bib23]). This stability combined with the good accessibility make circulating miRNAs attractive biomarker candidates. MiRNAs represent a class of promising biomarkers in cancer research since they are highly specific and are associated with pathoclinical parameters of the disease ([@bib27]). They can have protective or carcinogenic effects by post-transcriptional regulation of either tumour suppressor genes ([@bib35]) or oncogenes ([@bib25]). Since miRNAs are part of the cellular stress response they bear a high potential for diagnostic and prognostic use in cancer patients ([@bib17]).

The aim of the present study was to evaluate blood plasma miRNAs as minimally invasive biomarkers for radiotherapy monitoring and prognosis. For this purpose, we used a cohort of HNSCC patients with locally advanced and unresectable tumours undergoing radiochemotherapy or radiotherapy alone, which is the common treatment for these cases ([@bib2]). We previously analysed the therapy effect on the plasma miRNAs by comparing the miRNA profiles in plasma of HNSCC patients before therapy and after the completion of the first two fractions of therapeutic irradiation ([@bib28]). MiRNAs showing changed levels were tested in the present study to determine their prognostic value and their potential for predicting the individual tumour response to radio(chemo)therapy. For this purpose, we tested the expression levels of the miRNAs for their correlation with locoregional tumour control (LRC), progression-free survival (PFS) and overall survival (OS). To check for a possible tumour origin of the therapy-regulated plasma miRNAs, we compared miRNA levels in plasma samples from HNSCC patients prior to treatment with an age- and sex-matched group of healthy donors. MiRNAs that were identified as patient-specific markers or as therapy-responsive miRNAs were validated in an independent HNSCC patient cohort. To further support the hypothesis that the detected alterations in plasma miRNAs are tumour related, we analysed tumour biopsies from the same patient cohorts.

Materials and Methods
=====================

Patients and samples
--------------------

### Discovery cohort

The discovery cohort comprising 18 HNSCC patients treated with radio(chemo)therapy was described earlier in the study by [@bib28]. All patients were treated with local X-ray-irradiation using a linear accelerator (6 MV, Siemens Mevatron M, Siemens Medical Solutions, Malvern, PA, USA or ELEKTA Synergy, ELEKTA, Stockholm, Sweden). After a planning (PET-)CT scan, 70 Gy of radiation was applied to the macroscopic tumour and involved lymph nodes in daily dose fractions of 2 Gy, 5 days per week. The adjuvant lymphatics were irradiated with up to 50 Gy and the high-risk lymphatics (adjacent to the involved lymph node levels) with up to 60 Gy. Seventeen out of 18 patients received concurrent chemotherapy (13 patients received 5-fluorouracil (5-FU) plus mitomycin C (MMC), 3 patients MMC and 1 patient cisplatin weekly). None of the patients underwent surgical treatment. 5-fluorouracil treatment was usually applied on each of the first 5 days of therapeutic irradiation, whereas MMC was applied only on day 5 and day 36 during radiotherapy. Patient characteristics, therapy conditions and pathoclinical parameters are listed in [Table 1](#tbl1){ref-type="table"}. After obtaining informed consent, 15 ml EDTA peripheral blood was collected prior to therapy and after the second fraction of therapeutic irradiation to detect therapy-responsive plasma miRNAs. About 10 *μ*m formalin-fixed paraffin-embedded (FFPE) slides from tumour biopsies of 10 out of the 18 patients, which were retrieved prior to therapy, were provided by the Institute of Pathology at the Ludwig-Maximilians-University Munich.

### Validation cohort

For validation of candidate biomarker miRNAs a set of 11 HNSCC patients treated with radiotherapy was selected. Radiotherapy was applied in the same manner as in the discovery cohort. None of the patients underwent surgical treatment. Eight patients received concurrent chemotherapy (five patients cisplatin, two patients MMC and one patient 5-FU plus MMC). For patient 1, cisplatin was applied once per week. For patients 6, 8, 10 and 11 cisplatin was applied in the first and the fifth week of radiotherapy for a period of 5 days in each week. 5-fluorouracil treatment was applied on each of the first 5 days of therapeutic irradiation, whereas MMC was applied only on day 5 and day 36 during radiotherapy. Characteristics, therapy conditions and pathoclinical parameters of the validation cohort are listed in [Table 2](#tbl2){ref-type="table"}. Blood samples were obtained prior to therapy and after the second fraction of therapeutic irradiation in the same manner as in the discovery cohort. About 10 *μ*m FFPE slides from tumour biopsies of 4 out of the 11 patients retrieved prior to therapy were provided by the Institute of Pathology at the Ludwig-Maximilians-University Munich.

The study was approved by the ethics committee of the University of Munich (Germany).

### Healthy donors

Twelve age- and sex-matched controls were selected to elucidate the origin of the plasma miRNA signatures in HNSCC patients. The cohort comprised nine male and three female individuals with a median age of 57.2 years (age range 37--68 years). After obtaining informed consent, EDTA-samples of 8 ml of peripheral blood were collected from healthy volunteers.

RNA extraction from plasma and FFPE tissue
------------------------------------------

Total RNA was extracted from plasma according to the study by [@bib28].

Formalin-fixed paraffin-embedded-slides were deparaffinised in xylene, washed in isopropanol and rehydrated in ethanol (100 and 70%). After microdissection for removal of normal tissue, RNA was isolated using the RNeasy FFPE Kit (Qiagen, Venlo, Netherlands) following the manufacturer\'s protocol. RNA was eluted in RNAse-free water (Life Technologies, Carlsbad, CA, USA) with a final volume of 25 *μ*l. Quality assessment using a Nanodrop ND-1000 (Thermo Scientific, Waltham, MA, USA) exhibited OD 260/280 ratios in the range of 1.7 to 2.0.

MicroRNA profiling
------------------

MicroRNA profiling in blood plasma samples generated with TaqMan Array Human MicroRNA A Cards v2.0 (Applied Biosystems, Waltham, MA, USA) was previously specified in the study by [@bib28].

Individual miRNA quantification by qRT--PCR
-------------------------------------------

Quantification of individual miRNAs via qRT--PCR was performed as described before ([@bib28]). MiRNAs were considered deregulated when showing a fold change (FC) of 0.75⩽FC⩾1.33 since single qRT--PCR assays usually show smaller FCs than arrays.

Locoregional control and survival analysis
------------------------------------------

The locoregional control of the tumour was defined as the time from the date of therapy start until last follow-up/death or event. A progress of the primary tumour or metastases in the locoregional lymphatics were considered as an event, whereas distant metastases were not considered as an event. End of follow-up or tumour-independent death was censored. Locoregional control was assessed by CT scan or sonography. Progression-free survival was determined as the time from the date of therapy start until event (death or progress) or last follow-up (censored). Progress was assessed in accordance with the LRC analysis. Overall survival was defined as the time from diagnosis until event (death) or last follow-up (censored). The correlation analysis of miRNA expression with LRC, PFS and OS was based on the results of the single qRT--PCR assays. Patients were split into two groups, displaying either a ΔCt value ≥median ΔCt or \<median ΔCt for the miRNA of interest, referring to low and high expression levels, respectively. Expression levels prior to therapy or after therapy were tested for correlation with LRC, PFS and OS. *P*-values were generated by log-rank testing.

Statistical analysis
--------------------

The Mann--Whitney *U*-test was used to compare the plasma miRNA profiles of head and neck cancer patients before radiotherapy and healthy donors. To identify differential miRNA levels in plasma samples of patients prior to radiotherapy and after the second fraction of therapeutic irradiation the Wilcoxon test was performed. Unsupervised hierarchical clustering was performed using the top distinctive miRNAs applying the parameters maximum distance and Ward\'s method. *P*-values \<0.05 were considered statistically significant. All statistical analyses were performed using the [@bib1].

Results
=======

Plasma miRNAs differentiate between healthy individuals and HNSCC patients
--------------------------------------------------------------------------

To test the hypothesis of tumour-related miRNA profiles in the plasma of HNSCC patients (discovery cohort), miRNA profiles prior to treatment were compared with miRNA profiles of healthy donors. The median number of detectable miRNAs in patients\' plasma was 42.5, whereas the median number of detectable miRNAs in plasma samples of healthy donors was 33.0, which demonstrated a significantly (*P*=0.017) elevated number of plasma miRNAs in HNSCC patients compared with healthy subjects. About 56 plasma miRNAs displayed differential expression levels between healthy donors and patients ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The majority of miRNAs revealed lower expression levels in the healthy controls, only four miRNAs showed higher expression compared with patients. Unsupervised hierarchical clustering based on the expression levels of the top 8 differentially expressed miRNAs (*miR-21-5p*, *miR-28-3p*, *miR-142-3p*, *miR-186-5p*, *miR-191-5p*, *miR-197-3p*, *miR-425-5p* and *miR-590-5p*) resulted in two main clusters ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Cluster 1 included 7 healthy donors and 1 patient, while cluster 2 represented 17 patients and 5 healthy donors, which demonstrated a significant (*P*=0.003) differentiation of patient and healthy donor samples.

Technical validation of the array data for healthy donors and HNSCC patients prior to therapy was done with single qRT--PCR assays for selected miRNAs. Due to limited plasma samples, 3 out of 18 patients from the discovery cohort had to be excluded for technical validation. For validation of the patient-specific miRNAs, 11 out of the top 12 distinctive miRNAs were selected. The normalised Ct values resulting from single qRT--PCR assays demonstrated high consensus with the normalised Ct values resulting from the TaqMan array profilling for all of the 11 miRNAs ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

Plasma miRNAs that were detectable in ⩽1 healthy donor were tested for their ability to identify HNSCC patients ([Table 3](#tbl3){ref-type="table"}). *MiR-186-5p* demonstrated the highest sensitivity and specificity.

Validation of therapy-responsive and patient-specific plasma miRNAs in an independent cohort of HNSCC patients
--------------------------------------------------------------------------------------------------------------

For an independent validation of the patient-specific and therapy-responsive miRNAs identified in the discovery cohort, expression levels in the plasma of a validation cohort comprising 11 HNSCC patients were determined before therapy and after two fractions of radiotherapy. Each of the 9 candidate therapy-responsive miRNAs that were previously identified in the discovery cohort ([@bib28]) showed a deregulation in at least 7 out of the 11 patients in the validation cohort after 2 days of radiotherapy ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}). Similarly, all of the 10 patient-specific candidate miRNAs identified in the discovery cohort in the present study displayed significantly higher expression levels in the patients of the validation cohort compared with the healthy donors ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). *MiR-590-5p* was not included in the analysis of the patient-specific miRNAs since it was detectable only in 30% of the patients in the discovery cohort.

Expression of plasma miRNAs in tumour tissue of HNSCC patients
--------------------------------------------------------------

To further clarify the origin of the miRNAs in the circulation, we investigated the expression of therapy-responsive and patient-specific plasma miRNAs in tumour biopsies from the same patients. Formalin-fixed paraffin-embedded-tumour biopsies of 10 patients from the discovery cohort and 4 patients from the validation cohort were enriched for tumour material via microdissection and analysed with single qRT--PCR assays for the patient-specific and therapy-responsive miRNAs. All candidate miRNAs identified in plasma were also detectable in each of the 14 available FFPE tumour samples. The expression levels in plasma did not show significant correlation with the expression levels in the corresponding tumour tissues ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}).

Plasma miRNAs as prognostic markers
-----------------------------------

Plasma miRNAs that were identified previously as therapy-responsive candidates in HNSCC patients ([@bib28]) as well as tumour-specific miRNAs from the present study were tested for their ability to predict LRC, PFS and OS. We investigated if the expression level of a candidate miRNA prior to therapy or after the second day of treatment correlated with LRC, PFS or OS. We identified candidate miRNAs showing a significant correlation (*P*\<0.05) or a trend for correlation (*P*\<0.2) with LRC, PFS or OS in the discovery cohort ([Table 4](#tbl4){ref-type="table"}). High expression levels of *miR-186-5p*, *miR-374b-5p* and *miR-574-3p* prior to treatment correlated with reduced PFS and/or OS, and high expression of *miR-28-3p*, *miR-142-3p*, *miR-191-5p*, *miR-195-5p*, *miR-425-5p* and *miR-574-3p* after treatment showed correlation with worse prognosis. These candidate miRNAs were tested for correlation with LRC, PFS and OS in the validation cohort ([Table 5](#tbl5){ref-type="table"}). High expression of *miR-186-5p* and *miR-374b-5p* prior to treatment significantly correlated with reduced LRC. *MiR-195-5p* and *miR-574-3p* correlated with reduced LRC, when highly expressed after treatment. High expression of *miR-142-3p* after treatment was validated as a marker for reduced LRC and PFS. We also tested the HPV status as a predictor of LRC, which resulted in a trend (*P*=0.118) towards better LRC for HPV-positive cases in the discovery cohort (data not shown). Moreover, we tested the therapy-responsive and tumour-specific miRNAs for correlation with the HPV status. None of the candidate miRNAs showed a trend or a significant correlation with the HPV status (data not shown).

Discussion
==========

In this study we aimed to establish blood plasma miRNAs as minimally invasive biomarkers from the peripheral blood for therapy monitoring and prognosis in HNSCC patients. Further, we intended to shed light on the origin of these miRNAs. The significantly elevated number of detectable miRNAs in the plasma of HNSCC patients compared with healthy individuals is in accordance with previous findings showing that circulating miRNAs are frequently upregulated in cancer ([@bib16]; [@bib12]; [@bib30]). In our study we found that not only the total number of detectable miRNAs is higher in patients\' plasma compared with healthy individuals but also that the majority of miRNAs showed higher expression levels in patients compared with healthy donors. In the discovery cohort of HNSCC patients, a signature of *miR-21-5p*, *miR-28-3p*, *miR-142-3p*, *miR-191-5p*, *miR-186-5p*, *miR-197-3p*, *miR-425-5p* and *miR-590-5p* was identified to differentiate between HNSCC patients and healthy individuals. The fact that *miR-21-5p*, *miR-28-3p*, *miR-142-3p*, *miR-191-5p* and *miR-425-5p* also represented therapy-responsive miRNAs indicates that these miRNAs are indeed tumour related. Moreover, *miR-21-5p* is a well-known tumour marker ([@bib33]; [@bib36]) and upregulated *miR-28-3p* was suggested as a marker for oesophageal carcinoma ([@bib20]). *MiR-142-3p* was previously reported to serve as prognostic marker in oesophageal carcinoma ([@bib19]) and to predict the response to radiochemotherapy in rectal cancer ([@bib14]). Similarly, *miR-191-5p* was already described as an important biomarker in cancer ([@bib24]) and *miR-425-5p* was shown to predict survival and disease-free survival in skin cancer patients ([@bib8]). We were able to further support the hypothesis that the therapy-responsive plasma miRNAs are most likely tumour related by demonstrating expression of all candidate miRNAs in all available tumour tissues from our patient cohorts. The lack of significant correlation of expression levels in the tumour tissues with the expression levels of the corresponding plasma samples is not surprising. The various mechanisms of tumour miRNAs entering the blood stream, e.g. apoptotic tumour cells or active secretion ([@bib26]), do not allow the conclusion that tumour tissues show the same expression levels as corresponding plasma samples. Furthermore, tumour biopsies as used in this study do not reflect the miRNA expression levels of the whole tumour. Normal tissue would be also necessary for a meaningful comparison.

The therapy-responsive and the tumour-specific miRNAs identified in the discovery cohort were confirmed in an independent patient cohort again suggesting their suitability as predictive markers.

*MiR-186-5p* represented the best candidate in the plasma to differentiate between healthy individuals and HNSCC patients. It also appeared to be a prognostic marker since the expression level showed a trend for correlation with reduced PFS in the discovery cohort and significantly correlated with LRC in the validation cohort. A prognostic potential of *miR-186-5p* was previously reported for oesophageal and lung carcinoma ([@bib6]; [@bib34]). Circulating *miR-374b-5p* represents another promising prognostic marker since it exhibited significant correlation with PFS and OS in the discovery cohort and with LRC in the validation set prior to treatment. This is supported by a study suggesting a prognostic potential of this miRNA in prostate cancer ([@bib10]). The additional miRNA candidates *miR-142-3p, miR-195-5p* and *miR-574-3p* from this study correlated with prognosis after 2 days of treatment indicating that they might be useful tools for therapy monitoring.

*MiR-574-3p* is known as a stress-responsive miRNA, which was shown previously to serve as a prognostic marker in the serum of glioblastoma patients ([@bib22]). Moreover, it is published that it modulates the therapy response in breast cancer patients ([@bib32]), which makes it a promising candidate for therapy monitoring in HNSCC. Similarly, *miR-195-5p* is a well-known marker in the circulation of cancer patients ([@bib15]) and was previously identified as prognostic marker in oesophageal carcinoma ([@bib29]). The correlation of the therapy-responsive *miR-142-3p* with LRC suggests *miR-142-3p* as a marker for therapy success. An oncogenic role for *miR-142-3p* was shown in a previous study ([@bib21]) supporting the potential use of this miRNA as a prognostic biomarker. The ability to predict the response to therapy might decrease treatment failure and avoid patients\' exposure to the side effects of ineffective therapies. The applicability of all five miRNAs as prognostic markers is further supported by the fact that these miRNA markers represent obviously tumour-related miRNAs.

Circulating miRNAs are known to be deregulated in cancer and to predict early disease ([@bib11]). Their good availability as well as their stability makes them useful biomarker candidates. In the present study, we discovered *miR-142-3p*, *miR-186-5p*, *miR-374b-5p*, *miR-195-5p* and *miR-574-3p* as the most promising HPV-independent markers for prognosis in the plasma of HNSCC patients treated with combined radiochemotherapy. Studies including a higher number of patients are needed to further validate the prognostic value of these marker miRNAs. We further showed that the same miRNAs were significantly overexpressed in plasma of HNSCC patients compared to healthy individuals, which supports the hypothesis that they originate from the tumour. Our findings represent an important contribution towards a clinical use of plasma miRNAs for therapy monitoring and a potential use in personalised treatment strategies.
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###### Characteristics and clinical parameters of patients in the discovery set

  **Patient**   **Gender**    **Age (years)**[a](#t1-fn2){ref-type="fn"}  **Tumour site**     **Histology**    **TNM**[b](#t1-fn3){ref-type="fn"}   **HPV**   **Cumulative dose (Gy)**   **Concomitant therapy**  **Acute toxicity**[c](#t1-fn4){ref-type="fn"}    **Progress/death (event=1)**   **Locoregional control**[d](#t1-fn5){ref-type="fn"}**/overall survival**[e](#t1-fn6){ref-type="fn"} **(weeks)**
  ------------- ------------ -------------------------------------------- ------------------- --------------- ------------------------------------ --------- -------------------------- ------------------------- ----------------------------------------------- ------------------------------ -----------------------------------------------------------------------------------------------------------------
  1             M                                 80                      Larynx              SCC                          T3 N1a M0                  NA                 70                        MMC            Severe                                                       0/0                                                                   81.9/90.0
  2             M                                 70                      Oropharynx          SCC                          T2 N2c M0                  NA                 70                     5-FU/MMC          Severe                                                       0/1                                                                   38.3/40.9
  3             M                                 49                      Maxillary sinus     SCC                          T4 N2c M0                   −                 70                     5-FU/MMC          Mild                                                         1/1                                                                   15.0/18.9
  4             M                                 63                      Larynx              SCC                          T4 N2c M1                  \+                 60                     Cetuximab         Severe                                                       0/1                                                                   48.0/52.3
  5             F                                 63                      Oropharynx          SCC                           T3 N1 M0                  \+                 70                     5-FU/MMC          Severe                                                       0/1                                                                   57.1/61.1
  6             M                                 77                      Oropharynx          SCC                          T2 N2c M0                  \+                 70                     5-FU/MMC          Mild                                                         0/0                                                                  144.1/147.1
  7             M                                 52                      Oral cavity         SCC                          T4 N2b M0                  \+                 70                     5-FU/MMC          Severe                                                       1/1                                                                   16.9/39.4
  8             F                                 45                      Nasopharynx         SCC                          T2b N1 M0                   −                 70                     Cisplatin         Severe                                                       1/0                                                                  117.4/127.9
  9             M                                 54                      Paranasal sinuses   SCC                          T4b N0 M0                   −                 70                     5-FU/MMC          Severe                                                       0/0                                                                   8.3/21.3
  10            M                                 47                      Hypopharynx         SCC                          T4 N2c M0                   −                 70                     5-FU/MMC          Mild                                                         0/0                                                                  111.3/115.4
  11            F                                 79                      Oro/nasopharynx     SCC                          T3 N2b M0                   −                 70                     5-FU/MMC          Severe                                                       0/1                                                                   6.0/13.3
  12            M                                 50                      Larynx              SCC                          T4 N2c M0                   −                 70                     5-FU/MMC          Severe                                                       0/0                                                                  106.3/113.3
  13            M                                 46                      Larynx              SCC                          T1 N2c M0                   −                 70                     5-FU/MMC          Mild                                                         0/0                                                                   33.7/43.6
  14            F                                 78                      Oropharynx          SCC                          T1 N2b M0                  \+                 70                        MMC            NA                                                           0/0                                                                  103.3/108.9
  15            M                                 70                      Larynx              SCC                          T3 N2b M0                  NA                 70                     5-FU/MMC          Severe                                                       0/0                                                                  101.0/106.0
  16            M                                 57                      Oropharynx          SCC                           T3 N0 M0                  \+                 70                     5-FU/MMC          Mild                                                         0/0                                                                  103.3/93.0
  17            M                                 58                      Oral cavity         SCC                           T1 N1 M0                   −                 70                     5-FU/MMC          Severe                                                       1/1                                                                   4.1/43.7
  18            M                                 50                      Oral cavity         SCC                           T1 N0 M0                   −                 70                        MMC            Severe                                                       0/1                                                                   52.1/62.7

Abbreviations: F=female; HPV=human papillomavirus; M=male; MMC=mitomycin C; NA=not available; SCC=squamous cell carcinoma; 5-FU=5-fluorouracil.

age at diagnosis, median age: 57.5 years, age range (45.1--80.6 years).

T: primary tumour stage; N: regional lymph node stage; M: distant metastasis.

Mild: I°-II° severe: III° according to CTCAE v4.0 (2009).

Time from start of therapy until last follow-up/death or event.

Time from diagnosis until last follow-up or event.

###### Characteristics and clinical parameters of patients in the validation set

  **Patient**   **Gender**    **Age (years)**[a](#t2-fn2){ref-type="fn"}  **Tumour site**   **Histology**   **TNM**[b](#t2-fn3){ref-type="fn"}   **HPV**    **Cumulative dose (Gy)**  **Concomitant therapy**   **Acute toxicity**[c](#t2-fn4){ref-type="fn"}    **Progress/death (event=1)**   **Locoregional control**[d](#t2-fn5){ref-type="fn"}**/overall survival**[e](#t2-fn6){ref-type="fn"} **(weeks)**
  ------------- ------------ -------------------------------------------- ----------------- --------------- ------------------------------------ --------- -------------------------- ------------------------- ----------------------------------------------- ------------------------------ -----------------------------------------------------------------------------------------------------------------
  1             M                                 58                      Oropharynx        SCC             T3 N2c Mx                            −                     70             Cisplatin                 Mild                                                         0/0                                                                   13.3/20.9
  2             M                                 66                      Larynx            SCC             T2 N0 M0                             \+                    70             MMC                       Mild                                                         0/0                                                                   46.1/55.4
  3             M                                 77                      Oropharynx        SCC             T4 N2a M0                            \+                    70             MMC                       Severe                                                       0/0                                                                   47.0/55.1
  4             M                                 75                      Hypopharynx       SCC             T4 N2c M0                            −                     70             None                      Mild                                                         0/1                                                                   23.1/26.9
  5             F                                 69                      Oropharynx        SCC             T3 N2c M0                            NA                    70             5-FU/MMC                  Mild                                                         0/0                                                                   19.0/24.6
  6             M                                 55                      Hypopharynx       SCC             T4a N2b M0                           NA                    70             Cisplatin                 Mild                                                         1/0                                                                   32.4/36.3
  7             M                                 79                      Oropharynx        SCC             T2c N2c Mx                           NA                    70             None                      Mild                                                         1/0                                                                   31.3/36.3
  8             M                                 55                      Larynx            SCC             T3 N0 M0                             NA                    70             Cisplatin                 Mild                                                         0/0                                                                   13.6/20.1
  9             M                                 75                      Oropharynx        SCC             T3 N2 Mx                             NA                    70             None                      Mild                                                         0/0                                                                   19.0/25.3
  10            F                                 65                      Oropharynx        SCC             T4 N2b Mx                            NA                    70             Cisplatin                 Mild                                                         1/0                                                                   30.3/33.1
  11            M                                 65                      Oropharynx        SCC             T2 N0 M0                             NA                   70.4            Cisplatin                 Mild                                                         0/0                                                                   49.1/55.1

Abbreviations: F=female; HPV=human papillomavirus; M=male; MMC=mitomycin C; NA=not available; SCC=squamous cell carcinoma; 5-FU=5-fluorouracil.

Age at diagnosis, median age: 66.1 years, age range (55.0--79.8 years).

T: primary tumour stage; N: regional lymph node stage; M: distant metastasis.

Mild: I°-II° Severe: III° according to CTCAE v4.0 (2009).

Time from start of therapy until last follow-up/death or event.

Time from diagnosis until last follow-up or event.

###### Sensitivity and specificity of patient-specific plasma miRNAs expressed in ⩽1 healthy donor

  **miRNA**      **Sensitivity**   **Specificity**
  ------------- ----------------- -----------------
  miR-186-5p          0.938             0.917
  miR-374b-5p         0.312             1.000
  miR-28-3p           0.625             1.000
  miR-195-5p          0.562             1.000
  miR-590-5p          0.312             1.000

Abbreviation: miRNA=microRNA.

###### Correlation of expression of plasma miRNAs with LRC, PFS and OS in 15 HNSCC patients (discovery cohort)

  **miRNA**                           ***P*****-value LRC**   ***P*****-value PFS**   ***P***-**value OS**
  ---------------------------------- ----------------------- ----------------------- ----------------------
  miR-28-3p (after treatment)                 0.069                   0.027                  0.092
  miR-142-3p (after treatment)                0.129                    ---                    ---
  miR-186-5p (prior to treatment)              ---                    0.165                   ---
  miR-191-5p (after treatment)                0.129                   0.002                  0.004
  miR-195-5p (after treatment)                 ---                    0.029                  0.130
  miR-374b-5p (prior to treatment)             ---                    0.039                  0.036
  miR-425-5p (after treatment)                0.129                   0.002                  0.004
  miR-574-3p (prior to treatment)              ---                    0.165                   ---
  miR-574-3p (after treatment)                0.069                   0.027                  0.092

Abbreviations: HNSCC=head and neck squamous cell carcinoma; LRC=locoregional control; miRNA=microRNA; OS=overall survival; PFS=progression-free survival.

###### Correlation of expression of plasma miRNAs with LRC, PFS and OS in 11 HNSCC patients (validation cohort)

  **miRNA**                           ***P*****-value LRC**   ***P*****-value PFS**   ***P*****-value OS**
  ---------------------------------- ----------------------- ----------------------- ----------------------
  miR-142-3p (after treatment)                0.025                   0.018                   ---
  miR-186-5p (prior to treatment)             0.025                    ---                    ---
  miR-195-5p (after treatment)                0.025                    ---                    ---
  miR-374b-5p (prior to treatment)            0.025                    ---                    ---
  miR-574-3p (after treatment)                0.025                    ---                      

Abbreviations: HNSCC=head and neck squamous cell carcinoma; LRC=locoregional control; miRNA=microRNA; OS=overall survival; PFS=progression-free survival.
